Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | B7-H3 CAR T cells |
Synonyms | |
Therapy Description |
B7-H3 CAR T cells are T-cells engineered to express a chimeric antigen receptor (CAR) targeting B7-H3, which potentially inhibit growth of B7-H3-positive tumors (Cancer Res (2023) 83 (7_Supplement): 1197). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
B7-H3 CAR T cells | B7H3-CAR T|B7-H3CART | B7-H3 CAR T cells are T-cells engineered to express a chimeric antigen receptor (CAR) targeting B7-H3, which potentially inhibit growth of B7-H3-positive tumors (Cancer Res (2023) 83 (7_Supplement): 1197). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05835687 | Phase I | B7-H3 CAR T cells | Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors | Recruiting | USA | 0 |
NCT06646627 | Phase I | B7-H3 CAR T cells | Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors | Not yet recruiting | USA | 0 |